fcγr iii ko  (Jackson Laboratory)

Journal: JCI Insight

Article Title: Immunoglobulin replacement products protect against SARS-CoV-2 infection in vivo despite poor neutralizing activity

doi: 10.1172/jci.insight.176359

Figure Lengend Snippet: ( A and B ) Levels of XBB.1.5 RNA ( A ) and infectious virus ( B ) in the lungs of C57BL/6J ( n = 10, black dots) and FcγR I/III/IV–KO mice ( n = 10, red dots) challenged with SARS-CoV-2 XBB.1.5, 24 hours following administration of PBS or IG prophylaxis. Lungs were collected 2 days after inoculation for virological analysis. Mean values are shown (2 experiments). **** P < 0.0001 by 1-way ANOVA with Tukey’s posttest correction ( A and B ).

Article Snippet: FcγR I/III/IV–KO mice (lacking the common γ-chain) were commercially obtained sources (Taconic Biosciences, catalog 583) and then sequentially backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis ( ).

Techniques: Virus

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a-c) Levels of IgG1 (a), IgG2b (b), IgG2c (c) that bind to SARS-CoV-2 spike [Wuhan-1, B.1.617.2, BA.1, and BA.4/5], or influenza hemagglutinin (HA) in naïve and vaccine-induced immune sera. (d-f) Levels of spike- or HA-binding IgG antibodies that engage FcγR IIb (d), FcγR III (e), or FcγR IV (f) in naïve and vaccine-induced immune sera. (g-j) Antibody effector functions. Antibody-mediated cellular phagocytosis with monocytes (ADCP, g) or neutrophils (ADNP, h) activity using vaccine-induced immune (squares) or naïve (circles) sera and beads coated with SARS-CoV-2 Wuhan-1 and BA.4/5 spike proteins and murine monocytes (g-h) or human donors (i) (bars indicate mean ± SEM; n = 4 (g); n = 3 (h) mice per group, one experiment (g), two experiments (h); one-way ANOVA with Tukey’s post-test; ns, not significant; in order left to right **P = 0.0042, **P = 0.0083 (g); **P = 0.0012, *P = 0.0106 (h)). (i) CD107a surface expression on natural killer cells (ADNKA) after incubation with beads encoded with Wuhan-1 or BA4/5 spike proteins and immune sera (bars indicate median values; n = 2 donors per group, one experiment; one-way ANOVA with Tukey’s post-test; ns, not significant). (j) Deposition of complement (ADCD) on beads coated with indicated SARS-CoV-2 spike or influenza HA proteins after treatment with naïve or immune sera.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Binding Assay, Activity Assay, Expressing, Incubation

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of immunization, serum sampling, virus challenge, and tissue harvest. (b-c) Anti-Wuhan-1 (b) and BA.4/5 (c) RBD IgG responses from serum of mice immunized with control or mRNA-1273 vaccines. (d-e) Neutralizing antibody responses against WA1/2020 N501Y/D614G (d) and BA.5 (e) from serum collected from wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice 25 days after completion of a two-dose primary vaccination series with control (closed circles) or mRNA-1273 (open circles). (f-g) Nine-week-old male wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice were immunized twice at four-week intervals with control or mRNA-1273 vaccine via intramuscular route. Four weeks after the primary vaccination series, mice were challenged via intranasal route with 104 FFU of BA.5. At 3 dpi, infectious virus in the nasal turbinates (f) and lungs (g) was determined (boxes illustrate geometric mean titers [GMT], dotted lines show LOD, bars indicate mean ± SEM; in order left to right n = 10, 10, 10, 10, 25, 10, 10, 14 (b); n = 12, 10, 10, 10, 22, 10, 10, 15 (c); n = 22, 9, 9, 12, 30, 15, 15, 15 (d); n = 22, 9, 9, 12, 25, 10, 10, 15 (e); n = 19, 10, 8, 8, 19, 9, 10, 10 (f); n = 19, 10, 8, 8, 19, 9, 10, 10 (g) mice per group, one experiment (b-e), two experiments (f-g), dotted lines show LOD, one-way ANOVA with Dunnett’s test (ns, not significant, ***P = 0.002, ****P < 0.0001 (f); **P = 0.0044, ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Sampling, Virus, Vaccines

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of passive transfer, virus challenge and tissue harvest. (b) Neutralizing antibody responses against SARS-CoV-2 MA-10 using sera from naïve (circles) or Wuhan-1 spike protein vaccinated mice (pooled from animals immunized and boosted with mRNA-1273 or ChAd-SARS-CoV-2-S) (squares). Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice one day after transfer of immune sera. (c-g) Twelve-week-old male wild-type, C1q KO, and FcγR I/III/IV KO C57BL/6 mice were passively transferred by intraperitoneal injection 60 μL of naïve or vaccine-induced immune sera one day before intranasal challenge with 103 FFU of SARS-CoV-2 MA-10. At 4 dpi, viral RNA in the nasal wash (c), nasal turbinates (d), and lungs (f) was quantified, and infectious virus in the nasal turbinates (e) and lungs (g) was determined (bars indicate mean ± SEM; in order left to right n = 5 (b); n = 6, 6, 7, 7, 6, 7 (c); n = 6, 6, 7, 7, 6, 7 (d); n = 6, 6, 7, 7, 6, 7 (e); n = 6, 6, 7, 7, 6, 7 (f); n = 6, 6, 7, 7, 6, 7 (g) mice per group, one experiment (b), two experiments (c-g), dotted lines show limit of detection [LOD]). One-way ANOVA with Tukey’s post-test; ns, not significant; *P = 0.0188 (f); ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3. In c-g, the LOD are weight and volume based, and vary based on the amount of material collected for RNA extraction.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Virus, Activity Assay, Injection, RNA Extraction

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of passive transfer, virus challenge, and tissue harvest. (b) Neutralizing antibody response against SARS-CoV-2 WA1/2020 N501Y/D614G using sera from naïve (circles) or Wuhan-1 spike protein vaccinated (squares) mice. Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice one day after transfer of immune sera. (c-g) Twelve-week-old male wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice were passively transferred by intraperitoneal injection 60 μL of naïve or vaccine-immune sera one day before intranasal challenge with 104 FFU of WA1/2020 N501Y/D614G. At 4 dpi, viral RNA and infectious virus were measured in the upper respiratory tract (nasal wash, c; nasal turbinates, d-e; or lungs, f-g). Panels c-e: wild-type mice only; panels f-g: wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice (bars indicate mean ± SEM; in order left to right n =5 (b); n = 18, 11 (c); n = 18, 11 (d); n = 18, 11 (e); n = 18, 9, 9, 12, 10, 11, 8, 10, 11, 11 (f); n = 18, 9, 9, 12, 10, 11, 8, 10, 11, 11 (g) mice per group, one experiment (b), three experiments (c-g), dotted lines show LOD). One-way ANOVA with Tukey’s post-test (ns, not significant; **P = 0.0068, ****P < 0.0001 (f); ***P = 0.0002, ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Virus, Activity Assay, Injection

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Representative flow cytometry plots show gating scheme for quantification of spike-specific CD4+ and CD8+ T cell responses in the spleen of wild-type, FcγR III KO, and FcγR I/III/IV KO mice at day 10 after boosting with control or mRNA-1273 vaccines. (b-c) At day 10 after boosting, the spleen of wild-type and FcγR KO mice were harvested, and T cell responses were measured after spike peptide re-stimulation. Splenocytes were incubated overnight with class I MHC (b) or class II MHC (c) immunodominant spike peptides, and the percentages and numbers of IFNγ and TNFα positive CD8+ (b) or CD4+ (c) T cells were quantified by intracellular staining and flow cytometry. Data are pooled from two experiments (in order left to right n = 10, 10, 8, 10, 10, 9 (b-c)). Comparisons were made between groups that received the mRNA 1273 vaccine (one-way ANOVA with Tukey’s post-test; all comparisons were not significant; column height indicates mean values).

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Flow Cytometry, Vaccines, Incubation, Staining

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: Lung cells from wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice were stained with antibodies for FcγR I, FcγR III, or FcγR IV. After gating on live cells, alveolar macrophages, neutrophils, and monocytes were defined (see Extended Data Fig 5). The data are representative of results with n = 3 mice per group, and histograms are shown.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Staining

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a-c) Levels of IgG1 (a), IgG2b (b), IgG2c (c) that bind to SARS-CoV-2 spike [Wuhan-1, B.1.617.2, BA.1, and BA.4/5], or influenza hemagglutinin (HA) in naïve and vaccine-induced immune sera. (d-f) Levels of spike- or HA-binding IgG antibodies that engage FcγR IIb (d), FcγR III (e), or FcγR IV (f) in naïve and vaccine-induced immune sera. (g-j) Antibody effector functions. Antibody-mediated cellular phagocytosis with monocytes (ADCP, g) or neutrophils (ADNP, h) activity using vaccine-induced immune (squares) or naïve (circles) sera and beads coated with SARS-CoV-2 Wuhan-1 and BA.4/5 spike proteins and murine monocytes (g-h) or human donors (i) (bars indicate mean ± SEM; n = 4 (g); n = 3 (h) mice per group, one experiment (g), two experiments (h); one-way ANOVA with Tukey’s post-test; ns, not significant; in order left to right **P = 0.0042, **P = 0.0083 (g); **P = 0.0012, *P = 0.0106 (h)). (i) CD107a surface expression on natural killer cells (ADNKA) after incubation with beads encoded with Wuhan-1 or BA4/5 spike proteins and immune sera (bars indicate median values; n = 2 donors per group, one experiment; one-way ANOVA with Tukey’s post-test; ns, not significant). (j) Deposition of complement (ADCD) on beads coated with indicated SARS-CoV-2 spike or influenza HA proteins after treatment with naïve or immune sera.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Binding Assay, Activity Assay, Expressing, Incubation

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of immunization, serum sampling, virus challenge, and tissue harvest. (b-c) Anti-Wuhan-1 (b) and BA.4/5 (c) RBD IgG responses from serum of mice immunized with control or mRNA-1273 vaccines. (d-e) Neutralizing antibody responses against WA1/2020 N501Y/D614G (d) and BA.5 (e) from serum collected from wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice 25 days after completion of a two-dose primary vaccination series with control (closed circles) or mRNA-1273 (open circles). (f-g) Nine-week-old male wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice were immunized twice at four-week intervals with control or mRNA-1273 vaccine via intramuscular route. Four weeks after the primary vaccination series, mice were challenged via intranasal route with 104 FFU of BA.5. At 3 dpi, infectious virus in the nasal turbinates (f) and lungs (g) was determined (boxes illustrate geometric mean titers [GMT], dotted lines show LOD, bars indicate mean ± SEM; in order left to right n = 10, 10, 10, 10, 25, 10, 10, 14 (b); n = 12, 10, 10, 10, 22, 10, 10, 15 (c); n = 22, 9, 9, 12, 30, 15, 15, 15 (d); n = 22, 9, 9, 12, 25, 10, 10, 15 (e); n = 19, 10, 8, 8, 19, 9, 10, 10 (f); n = 19, 10, 8, 8, 19, 9, 10, 10 (g) mice per group, one experiment (b-e), two experiments (f-g), dotted lines show LOD, one-way ANOVA with Dunnett’s test (ns, not significant, ***P = 0.002, ****P < 0.0001 (f); **P = 0.0044, ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Sampling, Virus, Vaccines

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of passive transfer, virus challenge and tissue harvest. (b) Neutralizing antibody responses against SARS-CoV-2 MA-10 using sera from naïve (circles) or Wuhan-1 spike protein vaccinated mice (pooled from animals immunized and boosted with mRNA-1273 or ChAd-SARS-CoV-2-S) (squares). Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice one day after transfer of immune sera. (c-g) Twelve-week-old male wild-type, C1q KO, and FcγR I/III/IV KO C57BL/6 mice were passively transferred by intraperitoneal injection 60 μL of naïve or vaccine-induced immune sera one day before intranasal challenge with 103 FFU of SARS-CoV-2 MA-10. At 4 dpi, viral RNA in the nasal wash (c), nasal turbinates (d), and lungs (f) was quantified, and infectious virus in the nasal turbinates (e) and lungs (g) was determined (bars indicate mean ± SEM; in order left to right n = 5 (b); n = 6, 6, 7, 7, 6, 7 (c); n = 6, 6, 7, 7, 6, 7 (d); n = 6, 6, 7, 7, 6, 7 (e); n = 6, 6, 7, 7, 6, 7 (f); n = 6, 6, 7, 7, 6, 7 (g) mice per group, one experiment (b), two experiments (c-g), dotted lines show limit of detection [LOD]). One-way ANOVA with Tukey’s post-test; ns, not significant; *P = 0.0188 (f); ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3. In c-g, the LOD are weight and volume based, and vary based on the amount of material collected for RNA extraction.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Virus, Activity Assay, Injection, RNA Extraction

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Scheme of passive transfer, virus challenge, and tissue harvest. (b) Neutralizing antibody response against SARS-CoV-2 WA1/2020 N501Y/D614G using sera from naïve (circles) or Wuhan-1 spike protein vaccinated (squares) mice. Also shown is serum neutralizing antibody activity from recipient wild-type and FcγR I/III/IV KO mice one day after transfer of immune sera. (c-g) Twelve-week-old male wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice were passively transferred by intraperitoneal injection 60 μL of naïve or vaccine-immune sera one day before intranasal challenge with 104 FFU of WA1/2020 N501Y/D614G. At 4 dpi, viral RNA and infectious virus were measured in the upper respiratory tract (nasal wash, c; nasal turbinates, d-e; or lungs, f-g). Panels c-e: wild-type mice only; panels f-g: wild-type, FcγR I KO, FcγR II KO, FcγR III KO, and FcγR I/III/IV KO mice (bars indicate mean ± SEM; in order left to right n =5 (b); n = 18, 11 (c); n = 18, 11 (d); n = 18, 11 (e); n = 18, 9, 9, 12, 10, 11, 8, 10, 11, 11 (f); n = 18, 9, 9, 12, 10, 11, 8, 10, 11, 11 (g) mice per group, one experiment (b), three experiments (c-g), dotted lines show LOD). One-way ANOVA with Tukey’s post-test (ns, not significant; **P = 0.0068, ****P < 0.0001 (f); ***P = 0.0002, ****P < 0.0001 (g)); additional statistical comparisons are shown in Supplementary Table 3.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Virus, Activity Assay, Injection

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: (a) Representative flow cytometry plots show gating scheme for quantification of spike-specific CD4+ and CD8+ T cell responses in the spleen of wild-type, FcγR III KO, and FcγR I/III/IV KO mice at day 10 after boosting with control or mRNA-1273 vaccines. (b-c) At day 10 after boosting, the spleen of wild-type and FcγR KO mice were harvested, and T cell responses were measured after spike peptide re-stimulation. Splenocytes were incubated overnight with class I MHC (b) or class II MHC (c) immunodominant spike peptides, and the percentages and numbers of IFNγ and TNFα positive CD8+ (b) or CD4+ (c) T cells were quantified by intracellular staining and flow cytometry. Data are pooled from two experiments (in order left to right n = 10, 10, 8, 10, 10, 9 (b-c)). Comparisons were made between groups that received the mRNA 1273 vaccine (one-way ANOVA with Tukey’s post-test; all comparisons were not significant; column height indicates mean values).

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Flow Cytometry, Vaccines, Incubation, Staining

Journal: Nature microbiology

Article Title: Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2

doi: 10.1038/s41564-023-01359-1

Figure Lengend Snippet: Lung cells from wild-type, FcγR I KO, FcγR III KO, and FcγR I/III/IV KO mice were stained with antibodies for FcγR I, FcγR III, or FcγR IV. After gating on live cells, alveolar macrophages, neutrophils, and monocytes were defined (see Extended Data Fig 5). The data are representative of results with n = 3 mice per group, and histograms are shown.

Article Snippet: FcγR I KO 49 , FcγR II KO (Taconic Biosciences; Cat # 580), FcγR III KO (Jackson Laboratory; Cat # 009637), FcγR I/III/IV (common γ-chain) KO (Taconic Biosciences; Cat # 583), and C1q KO 50 mice were obtained commercially or from collaborators and then backcrossed onto a C57BL/6J background (>99%) using Speed Congenics (Charles River Laboratories) and single nucleotide polymorphism analysis.

Techniques: Staining